Tyra Biosciences
TYRA on Nasdaq. Pharmaceutical preparations. Market value $1.2bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-8.80 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$20.93 a share, 61% above its 1-year low
Over the past year the price has ranged from $12.98 to $40.65.
Pays no dividend
Prices from Monday’s close (5 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.04bn | 0.05bn | 0.05bn | 0.06bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 41% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $46 million, compared with a loss of $28 million a year ago.
- Over the past 12 months it spent $110 million more cash than it brought in, compared with $87 million a year earlier.
- 11% more shares than a year ago. Each share owns a bit less of the company.
| Quarter to | Amount |
|---|---|
| September 2024 | -$24m |
| December 2024 | -$26m |
| March 2025 | -$28m |
| June 2025 | -$28m |
| September 2025 | -$30m |
| December 2025 | -$34m |
| March 2026 | -$39m |
| June 2026 | -$46m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 2 March 2026
- Next quarterly (estimated, 10-Q)
- 3 November 2026
Who owns it
None of the long-term investors we follow own it. 170 funds in all.
Largest holders overall
- RA Capital Management, L.P.$390m
- FMR$285mAdded
- Jupiter Topco$139m
- Alta Partners Management Company, L.P.$122m
- Nextech Invest$114mCut
- TCG Crossover Management$104m
- BlackRock$97mAdded
- Price T Rowe Associates$89mAdded
- State Street$68mAdded
- Commodore Capital LP$60mCut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
10 investors own more than 5%.
- at least 19.9%−1.3 pts(filed with 3 related holders)Since 15 September 2026
- FMR LLCPassive investorat least 14.4%+11.2 pts(filed with 1 related holder)Since 31 March 2026
- JANUS HENDERSON GROUP PLCPassive investor7.2%+1.8 ptsSince 31 March 2026
- BVF PARTNERS L P/ILPassive investorat least 6.1%+2.1 pts(filed with 9 related holders)Since 14 September 2026
- Nextech VI Oncology SCSpPassive investorat least 6.0%(filed with 4 related holders)Since 30 June 2026
- Paradigm BioCapital Advisors LPPassive investorat least 5.8%(filed with 3 related holders)Since 10 September 2026
- TCG Crossover GP I, LLCPassive investorat least 5.7%(filed with 2 related holders)Since 27 February 2025
- BlackRock, Inc.Passive investor5.0%Since 30 June 2026
- Vestal Point Capital, LPPassive investorat least 4.5%−0.9 pts(filed with 1 related holder)Since 30 September 2025
- Commodore Capital LPPassive investorat least 4.2%−2.1 pts(filed with 3 related holders)Since 31 March 2026
- Todd HarrisPassive investorSold down below 5%Since 31 March 2026
- Canaan XI L.P.Passive investorSold down below 5%Since 31 March 2026
- Farallon Capital Partners, L.P.Passive investorSold down below 5%Since 31 March 2026
- Farallon Capital Management, L.L.C.Passive investorSold down below 5%Since 30 June 2026
| Holder | Stake | Since | |
|---|---|---|---|
at least 19.9%−1.3 pts (filed with 3 related holders) | 15 September 2026 | ||
FMR LLC Passive investor | at least 14.4%+11.2 pts (filed with 1 related holder) | 31 March 2026 | |
JANUS HENDERSON GROUP PLC Passive investor | 7.2%+1.8 pts | 31 March 2026 | |
BVF PARTNERS L P/IL Passive investor | at least 6.1%+2.1 pts (filed with 9 related holders) | 14 September 2026 | |
Nextech VI Oncology SCSp Passive investor | at least 6.0% (filed with 4 related holders) | 30 June 2026 | |
Paradigm BioCapital Advisors LP Passive investor | at least 5.8% (filed with 3 related holders) | 10 September 2026 | |
TCG Crossover GP I, LLC Passive investor | at least 5.7% (filed with 2 related holders) | 27 February 2025 | |
BlackRock, Inc. Passive investor | 5.0% | 30 June 2026 | |
Vestal Point Capital, LP Passive investor | at least 4.5%−0.9 pts (filed with 1 related holder) | 30 September 2025 | |
Commodore Capital LP Passive investor | at least 4.2%−2.1 pts (filed with 3 related holders) | 31 March 2026 | |
Todd Harris Passive investor | Sold down below 5% | 31 March 2026 | |
Canaan XI L.P. Passive investor | Sold down below 5% | 31 March 2026 | |
Farallon Capital Partners, L.P. Passive investor | Sold down below 5% | 31 March 2026 | |
Farallon Capital Management, L.L.C. Passive investor | Sold down below 5% | 30 June 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $20,000 of shares on the open market. 3 sold $11m, $10m of it under preset trading plans.
- Verjee RehanDirectorBought
- Date
- 9 September 2026
- Shares
- 972
- Price
- $20.58
- Value
- $20,000
- KAPLAN GILLADirectorSold
- Date
- 25 March 2026
- Shares
- 14,295
- Price
- $36.97
- Value
- $528,486
- Bensen DanielChief Discovery OfficerSoldunder a preset trading plan
- Date
- 12 February 2026
- Shares
- 8,000
- Price
- $32.87
- Value
- $262,981
- Bensen DanielChief Discovery OfficerSoldunder a preset trading plan
- Date
- 12 January 2026
- Shares
- 8,000
- Price
- $28.52
- Value
- $228,171
- MORE ROBERT JDirectorSoldunder a preset trading plan
- Date
- 19 December 2025
- Shares
- 10,000
- Price
- $25.00
- Value
- $250,000
- Bensen DanielChief Discovery OfficerSoldunder a preset trading plan
- Date
- 12 December 2025
- Shares
- 8,000
- Price
- $22.64
- Value
- $181,120
- MORE ROBERT JDirectorSoldunder a preset trading plan
- Date
- 21 November 2025
- Shares
- 246,871
- Price
- $20.25
- Value
- $5m
- Bensen DanielChief Operating OfficerSoldunder a preset trading plan
- Date
- 19 November 2025
- Shares
- 49,956
- Price
- $16.32
- Value
- $815,282
- Bensen DanielChief Operating OfficerSoldunder a preset trading plan
- Date
- 18 November 2025
- Shares
- 75,633
- Price
- $16.07
- Value
- $1m
- Bensen DanielChief Operating OfficerSoldunder a preset trading plan
- Date
- 17 November 2025
- Shares
- 20,072
- Price
- $16.18
- Value
- $324,800
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 9 September 2026 | Verjee Rehan Director | Bought | 972 | $20.58 | $20,000 |
| 25 March 2026 | KAPLAN GILLA Director | Sold | 14,295 | $36.97 | $528,486 |
| 12 February 2026 | Bensen Daniel Chief Discovery Officer | Sold under a preset trading plan | 8,000 | $32.87 | $262,981 |
| 12 January 2026 | Bensen Daniel Chief Discovery Officer | Sold under a preset trading plan | 8,000 | $28.52 | $228,171 |
| 19 December 2025 | MORE ROBERT J Director | Sold under a preset trading plan | 10,000 | $25.00 | $250,000 |
| 12 December 2025 | Bensen Daniel Chief Discovery Officer | Sold under a preset trading plan | 8,000 | $22.64 | $181,120 |
| 21 November 2025 | MORE ROBERT J Director | Sold under a preset trading plan | 246,871 | $20.25 | $5m |
| 19 November 2025 | Bensen Daniel Chief Operating Officer | Sold under a preset trading plan | 49,956 | $16.32 | $815,282 |
| 18 November 2025 | Bensen Daniel Chief Operating Officer | Sold under a preset trading plan | 75,633 | $16.07 | $1m |
| 17 November 2025 | Bensen Daniel Chief Operating Officer | Sold under a preset trading plan | 20,072 | $16.18 | $324,800 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.